More steroid-sparing options for #IgG4RD! Abstract 0775: In pts w/ IgG4: - Inebilizumab (CD19-monoclonal ab) vs placebo associated with reduced risk of flare (HR 0.13; 95% CI 0.06, 0.28) AEs: infections, infusion reactions, lymphopenia #ACR24 @RheumNow https://t.co/Vr5hcd2E7E